PAUL HOPKINS to Hyperlipoproteinemia Type II
This is a "connection" page, showing publications PAUL HOPKINS has written about Hyperlipoproteinemia Type II.
Connection Strength
4.131
-
Pharmacokinetic and pharmacodynamic assessment of alirocumab in patients with familial hypercholesterolemia associated with proprotein convertase subtilisin/kexin type 9 gain-of-function or apolipoprotein B loss-of-function mutations. J Clin Lipidol. 2019 Nov - Dec; 13(6):970-978.
Score: 0.582
-
Putting Into Perspective the Hazards of Untreated Familial Hypercholesterolemia. J Am Heart Assoc. 2017 06 26; 6(6).
Score: 0.496
-
Genotype-guided diagnosis in familial hypercholesterolemia: population burden and cascade screening. Curr Opin Lipidol. 2017 Apr; 28(2):136-143.
Score: 0.488
-
Genotype-guided diagnosis in familial hypercholesterolemia: clinical management and concerns. Curr Opin Lipidol. 2017 Apr; 28(2):144-151.
Score: 0.488
-
Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011 Jun; 5(3 Suppl):S9-17.
Score: 0.322
-
Defining the challenges of familial hypercholesterolemia screening: introduction. J Clin Lipidol. 2010 Sep-Oct; 4(5):342-5.
Score: 0.308
-
Soluble epoxide hydrolase variant (Glu287Arg) modifies plasma total cholesterol and triglyceride phenotype in familial hypercholesterolemia: intrafamilial association study in an eight-generation hyperlipidemic kindred. J Hum Genet. 2004; 49(1):29-34.
Score: 0.194
-
Familial hypercholesterolemia--improving treatment and meeting guidelines. Int J Cardiol. 2003 May; 89(1):13-23.
Score: 0.186
-
Evaluation of coronary risk factors in patients with heterozygous familial hypercholesterolemia. Am J Cardiol. 2001 Mar 01; 87(5):547-53.
Score: 0.160
-
Efficacy and Safety of Alirocumab in Patients With Autosomal Dominant Hypercholesterolemia Associated With Proprotein Convertase Subtilisin/Kexin Type 9 Gain-of-Function or Apolipoprotein B Loss-of-Function Mutations. Am J Cardiol. 2020 03 15; 125(6):880-886.
Score: 0.147
-
A novel LDLR mutation, H190Y, in a Utah kindred with familial hypercholesterolemia. J Hum Genet. 1999; 44(6):364-7.
Score: 0.138
-
Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia. J Clin Lipidol. 2017 Nov - Dec; 11(6):1338-1346.e7.
Score: 0.126
-
Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol. 1993 Jul 15; 72(2):171-6.
Score: 0.094
-
Type III dyslipoproteinemia in patients heterozygous for familial hypercholesterolemia and apolipoprotein E2. Evidence for a gene-gene interaction. Arterioscler Thromb. 1991 Sep-Oct; 11(5):1137-46.
Score: 0.083
-
Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011 Jun; 5(3 Suppl):S1-8.
Score: 0.081
-
Efficacy and safety of lovastatin therapy in adolescent girls with heterozygous familial hypercholesterolemia. Pediatrics. 2005 Sep; 116(3):682-8.
Score: 0.055
-
A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree. Hum Genet. 2004 Mar; 114(4):349-53.
Score: 0.049
-
Segregation analysis of HDL cholesterol in the NHLBI Family Heart Study and in Utah pedigrees. Eur J Hum Genet. 2002 Jun; 10(6):367-74.
Score: 0.044
-
Effects of three genetic loci in a pedigree with multiple lipoprotein phenotypes. Arterioscler Thromb. 1991 Sep-Oct; 11(5):1349-55.
Score: 0.021
-
The effect of genetic determinants of low density lipoprotein levels on lipoprotein (a). Clin Invest Med. 1991 Apr; 14(2):146-52.
Score: 0.020
-
Family-oriented nutrition intervention for a lipid clinic population. J Am Diet Assoc. 1991 Jan; 91(1):57-65.
Score: 0.020
-
Clinical application of deoxyribonucleic acid markers in a Utah family with hypercholesterolemia. Am J Cardiol. 1989 Jan 01; 63(1):109-12.
Score: 0.017
-
Prevention of familial cardiovascular disease by screening for family history and lipids in youths. Clin Chem. 1992 Aug; 38(8B Pt 2):1555-60.
Score: 0.006
-
Evidence for gene-environmental interactions in Utah families with hypertension, dyslipidaemia and early coronary heart disease. Clin Exp Pharmacol Physiol Suppl. 1992; 20:1-6.
Score: 0.005
-
Population-based frequency of dyslipidemia syndromes in coronary-prone families in Utah. Arch Intern Med. 1990 Mar; 150(3):582-8.
Score: 0.005